Holen Sie sich die Stockscreener-App
67.33
2.83%
1.85
Handel nachbörslich:
66.02
-1.31
-1.95%
Schlusskurs vom Vortag:
$65.48
Offen:
$66
24-Stunden-Volumen:
1.97M
Relative Volume:
0.78
Marktkapitalisierung:
$13.19B
Einnahmen:
$579.96M
Nettoeinkommen (Verlust:
$-729.89M
KGV:
-17.97
EPS:
-3.7459
Netto-Cashflow:
$-452.02M
1W Leistung:
-1.64%
1M Leistung:
-2.41%
6M Leistung:
-9.91%
1J Leistung:
+77.09%
1-Tages-Spanne:
$65.14
$68.48
1-Wochen-Bereich:
$62.50
$68.48
52-Wochen-Spanne:
$37.69
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
67.33 | 12.82B | 579.96M | -729.89M | -452.02M | -3.7459 |
VRTX
Vertex Pharmaceuticals Inc
|
441.74 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
628.73 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
842.27 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.64 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
155.69 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-03-10 | Eingeleitet | William Blair | Outperform |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BBIO: Attruby’s rapid growth and differentiated data anchor a pipeline poised for multiple rare disease launches - TradingView
BBIO: Attruby's rapid growth and differentiated data drive momentum as multiple rare disease launches near - TradingView
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio (BBIO) Receives Buy Rating with $104 Target by Canacco - GuruFocus
Precision Trading with Bridgebio Pharma Inc. (BBIO) Risk Zones - Stock Traders Daily
BridgeBio Pharma director Ellis Andrea sells $4.2m in shares - Investing.com
Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $82 - Moomoo
Biotech BridgeBio hands new recruits 31,428 stock units - Stock Titan
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a Promising 54.93% Upside Potential - DirectorsTalk Interviews
Does FDA Priority Review for First LGMD Therapy Change The Bull Case For BridgeBio Pharma (BBIO)? - Yahoo Finance
BridgeBio gains as muscular dystrophy therapy gets FDA priority review - MSN
Farallon funds hold multi‑million share positions in BridgeBio (NASDAQ: BBIO) - Stock Titan
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98. - GuruFocus
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98.00 - GuruFocus
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110 - Moomoo
BBIO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $110 - GuruFocus
FDA accepts BridgeBio’s BBP-418 for priority review - The Pharma Letter
BridgeBio (BBIO) Secures FDA Filing Acceptance for BBP-418 - GuruFocus
FDA grants Priority Review to BridgeBio (NASDAQ: BBIO) BBP-418 NDA - Stock Titan
BridgeBio Pharma (BBIO) Shares Rise on FDA Priority Review for B - GuruFocus
BridgeBio Pharma (BBIO) Shares Rise on FDA Priority Review for BBP-418 - GuruFocus
BridgeBio gains FDA review for muscle disorder drug (BBIO) - Seeking Alpha
BridgeBio’s LGMD2I/R9 drug receives FDA priority review By Investing.com - Investing.com Nigeria
BridgeBio Pharma Announces FDA Acceptance of BBP-418 NDA for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Priority Review Status - Quiver Quantitative
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 - The Manila Times
BridgeBio’s LGMD2I/R9 drug receives FDA priority review - Investing.com
FDA priority review for first potential LGMD2I/R9 treatment - Stock Titan
Raymond James downgrades BridgeBio Pharma (BBIO) - MSN
BridgeBio Pharma Shares Fall After Raymond James Downgrade - Moomoo
Bridgebio Pharma Insider Sold Shares Worth $1,812,522, According to a Recent SEC Filing - Moomoo
BridgeBio (BBIO) CEO Neil Kumar sells 26,103 shares in Rule 10b5-1 trades - Stock Titan
BBIO Downgraded by Raymond James -- Rating Changed to Market Per - GuruFocus
BridgeBio Pharma (BBIO) Downgraded by Raymond James Amid Competi - GuruFocus
Breakeven On The Horizon For BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Moomoo
BridgeBio Pharma (BBIO) Downgraded by Raymond James Amid Competitive Pressures - GuruFocus
BridgeBio downgraded at Raymond James on LOE for Pfizer’s Vyndamax - Seeking Alpha
Raymond James Downgrades BridgeBio Pharma to Market Perform From Outperform - marketscreener.com
Raymond James downgrades BridgeBio Pharma stock rating on payer risks By Investing.com - Investing.com Canada
BridgeBio Pharma Shares Drop After Downgrade by Raymond James - Intellectia AI
BridgeBio Pharma, Inc. (BBIO) Growth Potential: Analyst Ratings Signal 47% Upside - DirectorsTalk Interviews
Technical Reactions to BBIO Trends in Macro Strategies - Stock Traders Daily
BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute - MSN
BBIO (NASDAQ: BBIO) trust sells repeated 20,000-share blocks under 10b5-1 - Stock Titan
BBIO Stock Price Prediction 2025-2026 | BridgeBio Pharma Inc Forecast - 24/7 Wall St.
BridgeBio’s SWOT analysis: rare disease stock eyes profitability By Investing.com - Investing.com Canada
BridgeBio’s SWOT analysis: rare disease stock eyes profitability - Investing.com
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cullinan Management (CGEM) - The Globe and Mail
BBIO Initiates Coverage by Citigroup -- Rating Set to Neutral - GuruFocus
J.P. Morgan Initiates BridgeBio Pharma(BBIO.US) With Hold Rating, Announces Target Price $82 - Moomoo
Bridgebio Pharma Insider Sold Shares Worth $671,456, According to a Recent SEC Filing - Moomoo
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.89%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):